
ASCO 2026
9 interviews1 hr 19 min
American Society of Clinical Oncology Annual Meeting
Chicago, USA
Interviews and expert commentary from ASCO 2026 — study authors and key opinion leaders discuss the findings and their clinical implications.
Official website ↗
David R Spigel MD; ASCO 2026: Bispecific PD-1/VEGF Antibody Ivonescimab Extends Life in Patients with Untreated Advanced Non–Small Cell Lung Cancer: Phase 3 HARMONi-6 trial
CHICAGO, USA—The bispecific antibody ivonescimab (that targets the PD-1 and VEGF molecules) has extended overall survival in patients with untreated advanced squamous non-small cell lung cancer in…

Vanita Noronha MD; ASCO 2026: Ultra-Low Dose Immunotherapy Extends Life with Metastatic Head and Neck Cancer at Low Cost for Patients in Low and Middle Income Countries
CHICAGO, USA—Although recurrent or metastatic head and neck cancers respond well to palliative chemotherapy with immune checkpoint inhibition, this approach may be un-affordable in low and middle…

John Mascarenhas MD; ASCO 2026: New Janus Kinase Inhibitor Improves Myelofibrosis Outcomes When Added to Ruxolitinib Initial Therapy
CHICAGO, USA—Outcomes were improved for patients with myelofibrosis in the phase 3 SENTRY trial who were randomized to have the new Janus kinase inhibitor selinexor added to their ruxolitinib initial…

David R Spigel MD; ASCO 2026: EGFR Exon-20 Insertion Directed Initial Therapy Cuts Disease Progression in Patients with Advanced Non-Small Cell Lung Cancer
CHICAGO, USA—For patients with advanced non-small cell lung cancer harboring the rare exon-20 gene insertion,first-line treatment with the targeted drug sunvozertinib monotherapy brought…

Robert C. Stein, PhD FRCP; ASCO 2026: Gene Test Finds Most Patients with High Risk ER-positive, HER2-negative Early Breast Cancer Do Not Benefit from Chemotherapy
The idea that all women with hormone dependent early breast cancers that test negative for the HER2 molecule and have high risk clinical factors should be receive chemotherapy in addition to…

Bjørn Henning Grønberg MD PhD; ASCO 2026: Adding Thoracic Radiotherapy Did Not Prolong Lives of Patients with Extensive Stage Small Cell Lung Cancer Being Treated with Chemo-Immunotherapy. COMMENT: David R Spigel MD
Patients with extensive stage small cell lung cancer did not live longer with thoracic radiotherapy added to their chemo-immunotherapy in a study reported to the American Society of Clinical Oncology…

Kevin Kalinsky MD; ASCO 2026: ASCENT-04 Study Finds Sacituzumab Govitecan plus Pembrolizumab Helps Patients with Previously Untreated Metastatic PD-L1 Positive Triple Negative Breast Cancer Live Longer Without Progression Beyond Subsequent Therapies
CHICAGO, USA—Combining the antibody-drug conjugate sacituzumab govitecan with pembrolizumab immunotherapy for patients with metastatic triple-negative breast cancers testing positive for the…

Wing-Lok Chan MBBS; 2026 ASCO: Patients with Advanced Cancer Using The SUPPORT+ Mobile Phone App With Nurse Supervision have Better Quality of Life and Fewer Hospitalizations
An interview with: Wing-Lok Chan MBBS, Clinical Associate Professor, Department of Clinical Oncology, The University of Hong Kong, Hong Kong, China CHICAGO, USA—Patients with advanced cancer had…

Ghassan K. Abou-Alfa MD PhD; ASCO 2026: Adding Doublet Immune Checkpoint Inhibition to Embolization with or without anti-Growth Factor TKI Therapy Extends Progression Free Survival in Patients with Hepatocellular Cancer
CHICAGO, USA—Patients with unresectable liver cancers who were eligible for treatment with transarterial chemoembolization (TACE), were randomly offered, treatment with the anti-CTL-4 checkpoint…